Soft tissue sarcoma (STS)

Researchers are testing an oral drug called AL58805, which blocks two cancer-growth proteins, PI3K and mTOR, in adults with advanced endometrial, cervical, soft tissue sarcoma, or breast cancers that have worsened after at least one standard treatment. Participants receive AL5880…

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

This trial tests SOT106, a cancer medicine designed to find and kill cells that carry a marker called LRRC15, which appears on some osteosarcoma and soft tissue sarcoma tumors. The study has two parts: the first finds safe dose levels, and the second compares two doses to see whi…

This phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …

This Phase 2 trial tests two drugs, OVV-01 and AK112, given together every two weeks to 40 adults with advanced soft tissue sarcoma that has not responded to standard treatments. The main goal is to see if the combination can shrink tumors safely. Researchers will also measure ho…

This study looks at whether adding an immunotherapy drug (penpulimab) to standard pre-surgery radiation and a targeted therapy (anlotinib) can help people with soft tissue sarcoma live longer without the cancer coming back. About 274 adults with intermediate- to high-grade sarcom…

This trial is testing whether giving a special type of radiation (ultra-hypofractionated) along with immunotherapy before surgery is safe and feasible for people with retroperitoneal sarcoma. The study will enroll 28 participants. The main goal is to see how many patients have co…

This phase 2 trial is testing a new treatment for soft tissue sarcoma that combines a special type of radiation with immunotherapy and immune-boosting drugs. The goal is to see if this combination can shrink tumors and improve outcomes for people with advanced or recurrent sarcom…

This phase 2 trial tests a combination of the immunotherapy epalrotokewali, chemotherapy eribulin, targeted therapy anlotinib, and radiotherapy in 46 people with advanced soft tissue sarcoma that has progressed after prior treatment. The goal is to see if this mix can shrink tumo…

This trial tests whether a personalized, smartwatch-supported home exercise program can increase physical activity and improve heart health, mobility, and quality of life in adolescents and young adults who have survived bone or soft tissue sarcoma. Participants wear a fitness tr…

This early-stage study tests whether a fluorescent dye called 5-ALA can make soft-tissue sarcoma tumors glow during surgery, helping surgeons see the edges more clearly. About 20 adults with grade 2 or 3 sarcoma will take the dye by mouth before their standard surgery. The main g…